BioCryst Pharmaceuticals stock (US09058V1035): Shares surge 9% after earnings

BioCryst Pharmaceuticals (BCRX) shares jumped 9.09% to $9.60 on May 13, 2026, following Q1 earnings release showing revenue growth despite EPS miss. Analysts maintain Moderate Buy rating with $20.70 target.

BioCryst Pharmaceuticals stock surged 9.09% on May 13, 2026, closing at $9.60 on Nasdaq after the company reported first-quarter earnings. Revenue rose 7.5% year-over-year to an unspecified amount, though EPS came in at ($2.98), missing consensus estimates of $0.06, according to MarketBeat as of May 14, 2026. Year-to-date, shares are up 23.1% from $7.80 at the start of 2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: BioCryst Pharmaceuticals, Inc.
• Sector/industry: Biotechnology / MED - DRUGS
• Headquarters/country: Durham, North Carolina, USA
• Core markets: Rare diseases, hereditary angioedema
• Key revenue drivers: Oral small-molecule therapies
• Home exchange/listing venue: Nasdaq (BCRX)
• Trading currency: USD

BioCryst Pharmaceuticals: core business model

BioCryst Pharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing novel oral small-molecule medicines for rare and serious diseases. Headquartered in Research Triangle Park, North Carolina, the firm targets conditions like hereditary angioedema (HAE) with treatments such as ORLADEYO, its approved oral therapy. The company, founded in 1986, employs around 530 people and lists on Nasdaq under BCRX.

This model emphasizes innovation in rare disease spaces, where high unmet needs allow for premium pricing and orphan drug status benefits. BioCryst advances pipeline candidates through clinical trials while commercializing approved products, generating revenue primarily from US and global sales of HAE prophylactics. For US investors, its Nasdaq listing and exposure to the growing $10B+ rare disease market provide direct access to biotech upside.

Main revenue and product drivers for BioCryst Pharmaceuticals

Key revenue stems from ORLADEYO (berotralstat), the first oral once-daily prophylaxis for HAE attacks in patients 12 years and older. Approved by the FDA, it addresses a critical need in a market projected to grow significantly. Q1 2026 revenue increased 7.5% year-over-year, per the May 6 earnings release published on MarketBeat as of May 14, 2026.

Pipeline progress includes real-world evidence presentations, such as upcoming data at ISPOR 2026 (May 17-20) underscoring pediatric HAE burden, announced May 13 via GlobeNewswire. This supports market expansion. For US investors, BioCryst's focus on high-barrier rare disease therapies ties into domestic healthcare spending trends.

Industry trends and competitive position

The biotechnology sector, particularly rare diseases, benefits from orphan drug incentives and rising diagnostics. Competitors like Halozyme (HALO) and Repligen (RGEN) operate in adjacent spaces, but BioCryst differentiates with oral HAE focus. Its market cap stands at $2.44B with 18.95M shares traded on May 13, per MarketBeat data.

Why BioCryst Pharmaceuticals matters for US investors

Listed on Nasdaq, BioCryst offers US investors exposure to innovative biotech without foreign exchange risks. Its HAE franchise taps into the US-dominated rare disease market, where payers reimburse high-cost therapies. YTD gains of 23.1% reflect sector momentum amid clinical advancements.

Conclusion

BioCryst Pharmaceuticals reported Q1 revenue growth amid an EPS miss, driving a 9% share surge to $9.60 on May 13, 2026. Upcoming ISPOR data highlights pediatric HAE focus, while analysts see 115% upside to $20.70. The stock's Nasdaq presence and rare disease pipeline position it amid biotech volatility, with YTD gains underscoring momentum for US portfolios.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.